Kinsella Group Research
Advisory Approach
Kinsella Group is a boutique investment bank that focuses exclusively on the MedTech sector, representing sellers and acquirers of companies in medical device contract manufacturing, medical products, and healthcare technology. The firm operates with a highly specialized thesis: deep MedTech domain expertise generates superior transaction outcomes. Their sweet spot is founder-owned and family-owned MedTech businesses, particularly contract manufacturers of medical devices, orthopedic implants, surgical instrumentation, and precision medical components.
What sets Kinsella Group apart is their "buyer's eye" perspective—the firm has a long history of representing both financial and strategic acquirers in buy-side mandates, which gives them unique insight into what buyers value when evaluating sellers. This dual representation experience informs their sell-side counsel, allowing them to position clients for optimal outcomes by understanding acquisition criteria from the buyer's perspective.
Sector Focus
Kinsella Group serves the MedTech sector exclusively. Their primary focus areas include:
Contract Manufacturing: Medical device contract manufacturing represents the firm's deepest expertise. They work with precision machining companies, laser processing specialists, and complex assembly providers serving orthopedic OEMs. Their team includes former operators who understand plant-level operations, quality systems, and the technical requirements of medical device manufacturing.
Orthopedic Devices: The firm has completed numerous transactions involving orthopedic implants, spinal implants, surgical instruments, and extremity products. Their team includes executives with extensive experience at major orthopedic companies like Abbott, Zimmer, Guidant, and Acumed.
Surgical Instrumentation: From minimally invasive surgery components to complex surgical instruments, Kinsella Group understands the technical and market dynamics of this specialized segment.
The firm's exclusivity to MedTech is a deliberate strategy—rather than being generalists who dabble in healthcare, they are MedTech specialists who understand regulatory considerations, quality systems, OEM relationships, and the technical nuances that drive value in medical technology transactions.
Deal Track Record
Kinsella Group has successfully closed dozens of transactions throughout their history, with particularly strong activity in orthopedic contract manufacturing. The firm reports that 83% of their buy-side clients have issued a Term Sheet or IOI with a prospect generated by Kinsella Group—a testament to their targeted acquisition search capabilities.
Representative transactions include:
Sell-Side Transactions:
- Integrated Medical Solutions (Ohio-based spine implant contract manufacturer) sold to Avalign Technologies (portfolio company of Linden Capital Partners)
- Advantage Manufacturing Technologies (Washington-based orthopedic implant and instrument manufacturer) sold to Medin Technologies (portfolio company of Seven Point Equity Partners)
- Southeastern Technology (Tennessee-based medical device contract manufacturer) sold to Autocam Medical
- Onyx Medical (Tennessee-based trauma and extremity products) sold to Elos Medtech (Sweden-based strategic buyer)
- Medin Corporation sold to Seven Point Equity Partners
- Jade Precision Medical Components sold to ARCH Global Precision
- JEC sold to ARCH Global Precision
- Direct Medical Data (healthcare software) sold to Aptilon Holdings
- Veracity Medical Solutions (complex surgical instruments) sold to Heron Capital
Buy-Side Transactions:
- Precision Edge Surgical Products (Michigan-based contract manufacturer) acquired Eva-Lution (Indiana-based instrument manufacturer) — Kinsella conducted exclusive buy-side search
- Marle Group (France-based orthopedic implant manufacturer) acquired majority stake in Tangible Solutions (3D printed titanium implants) — Kinsella conducted exclusive buy-side search
- Schivo Medical (Ireland-based life sciences contract manufacturer) acquired Supreme Screw Products (New York-based precision parts supplier) — Kinsella conducted exclusive buy-side search
- Tecomet (portfolio company of Charlesbank Capital Partners) acquired Teleflex Ortho Business — Kinsella conducted targeted acquisition search
- Avalign Technologies acquired assets of Thortex
These transactions demonstrate Kinsella Group's ability to:
- Access off-market opportunities—many of their buy-side deals were with companies not actively for sale
- Navigate cross-border transactions with European and Asian buyers
- Work with both strategic buyers and private equity sponsors
- Close complex transactions in technical niches where domain expertise matters
Process & Fee Structure
Kinsella Group runs a highly disciplined, research-driven process for both buy-side and sell-side mandates.
Sell-Side Process: For seller representation, the firm conducts thorough preparation including Confidential Information Memorandum development, buyer identification, and structured negotiation. In one representative case, they contacted ~60 prospective buyers, generated 21 NDA executions, received seven indications of interest, conducted five management meetings, and negotiated three letters of interest—ultimately closing the transaction. Their process typically takes 9-12 months from engagement to close, consistent with lower middle market sell-side timelines.
Buy-Side Process: Their acquisition search is characterized by deep industry networking and proprietary deal flow. The firm's philosophy is that "research, dogged pursuit and rapport-building are critical" to success. They frequently identify targets that are not actively marketed, leveraging their MedTech network to access off-market opportunities. This approach has led to a high success rate—83% of buy-side clients reach the IOI/term sheet stage with Kinsella-generated prospects.
Fee Structure: The firm operates as FINRA-registered securities agents through Burch & Company, Inc., allowing them to charge success-based fees for transactions involving stock or debt. While specific fee ranges are not published on their website, their engagement model is consistent with lower middle market investment banking: retainers credited against success fees, with the success fee structure likely following Lehman or modified Lehman formulas based on transaction value.
Buyer Network
Kinsella Group has cultivated deep relationships across multiple buyer categories in the MedTech space:
Private Equity Sponsors: The firm has closed transactions with numerous PE-backed platforms including Avalign Technologies (Linden Capital Partners), Medin Technologies (Seven Point Equity Partners), and Tecomet (Charlesbank Capital Partners). They understand PE investment criteria, portfolio add-on strategies, and the dynamics of working with PE sponsors and their management teams.
Strategic Buyers: Their buyer network includes major strategic acquirers like Elos Medtech (Sweden), Autocam Medical, Schivo Medical (Ireland), Marle Group (France), and ARCH Global Precision. This global strategic base provides access to buyers with synergistic motivations and the ability to pay strategic premiums.
Family Offices and Corporate Buyers: The firm has worked with family offices and corporate acquirers, bringing a flexible approach to buyer type based on seller objectives.
What distinguishes Kinsella Group's buyer network is the depth of relationships within MedTech contract manufacturing and orthopedics—they don't just know who buys MedTech companies, they understand the specific capabilities, technologies, and market positions that different strategic and PE buyers seek.
Competitive Positioning
Kinsella Group differentiates from other lower middle market M&A advisors through three key attributes:
Exclusivity to MedTech: While many investment banks claim healthcare expertise, Kinsella Group is MedTech-pure. They don't serve providers, pharma, or other healthcare segments—they focus entirely on medical technology, device manufacturing, and related sectors. This specialization allows for deeper domain knowledge, stronger industry relationships, and more credible positioning with MedTech buyers and sellers.
Buy-Side Heritage Gives "Buyer's Eye": The firm's extensive experience representing acquirers provides unique insight into buyer psychology. They understand how buyers evaluate acquisitions, what makes a CIM compelling, and how to position sellers to maximize value. This perspective is rare among sell-side advisors who lack buy-side representation experience.
Operating Experience: Team members include former MedTech executives who have run businesses, launched products, managed manufacturing operations, and sat in buyer seats. This operating experience allows them to speak the language of MedTech founders and understand operational considerations that drive transaction value.
Global Reach: With experience spanning the U.S., Europe, and Asia, and team members who have lived and worked internationally, Kinsella Group can access cross-border opportunities that domestic-only advisors cannot reach.
Not a Fit If
Kinsella Group is likely not the right advisor for:
- Businesses outside the MedTech sector—their exclusivity to medical technology means they decline engagements in other industries
- Companies seeking a "limited process" or negotiated sale to a single buyer—Kinsella believes in creating competitive tension to maximize value
- Sellers wanting a generalist healthcare banker—their value proposition is MedTech specialization, not broad healthcare coverage
- Transactions requiring public company advisory or capital markets access—their focus is private company M&A in the lower middle market
Team
Kinsella Group is led by a team of experienced MedTech investment professionals with over 110 collective years of experience consulting with or operating MedTech businesses.
Robert J. Kinsella, President & Founder: Bob founded Kinsella Group and serves as President. He is an SEC/FINRA registered Broker/Dealer Representative with Series 62, 63, and 79 licenses. Prior to founding the firm, he acquired 12 companies across printing, automotive parts, and office furniture distribution. He holds an MBA from Northwestern Kellogg and a BS from the University of Missouri. He is a U.S. Navy veteran.
Daniel J. Greene, Managing Director: Dan has over 20 years of experience operating and advising businesses, with expertise in acquisitions, financial performance improvements, and post-merger integration. During his Kinsella Group tenure, he has worked on over 50 successful acquisitions in MedTech, manufacturing, and business services. He is an SEC/FINRA registered representative with Series 79 and 63 licenses, and holds a Bachelor's degree, MBA in Finance, and Master of Accounting degree.
Curt Jennewine, Managing Director: Curt is a Medical Device Executive with over 25 years of sales, marketing, and operational success at companies including Abbott, Zimmer, Guidant, and Acumed. He has worked with numerous medical technologies including orthopedics, trauma, spine, vascular intervention, cardiac rhythm management, and diabetes. He holds a Master of Management from Kellogg School of Management and a BA from Duke University. He is fluent in Japanese and conversational in German.
Michael Magnani, Managing Director: Mike brings over 20 years of healthcare experience across biotechnology, pharmaceutical, and medical device industries. Previously President of CLS Americas and founding CEO of two MedTech startups (Saranas, acquired by Johnson & Abiomed; StimAire). He holds an MS from Harvard Medical School, an MBA from MIT Sloan, and a BS from UC San Diego.
David Brooks, Director, M&A: Dave has held senior executive roles in orthopedics, healthcare, and scientific instrument industries. Most recently President of Medplast International prior to its acquisition by Viant Medical. Based in the U.K., he has extensive experience across Europe, Asia, and the Americas. He holds an MBA from Open University and is a certified CIMA accountant.
Geographic Coverage
Kinsella Group is headquartered in Chicago, Illinois (200 South Wacker Drive, Suite 3100). The firm serves clients across North America, with recent transaction experience in Michigan, Ohio, Tennessee, Washington, and Massachusetts. Through team members based in the U.K. and extensive international experience, they also serve European and Asian clients, having completed transactions with buyers in Ireland, France, Sweden, and across the EU. Their global perspective—honed from offices in Shanghai and extensive work in Europe and Asia—allows them to facilitate cross-border MedTech transactions that domestic-only advisors cannot execute.
The firm's international capability is particularly valuable for MedTech sellers seeking access to European strategic buyers or for non-U.S. buyers seeking U.S. MedTech acquisition targets. This cross-border expertise, combined with deep MedTech specialization, creates a differentiated value proposition in the lower middle market.